查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301022

药物器械组合产品的市场规模、份额和趋势分析报告：按产品（透皮贴剂、输液泵、吸入器、药物洗脱支架）、按地区、细分市场趋势，2023-2030年

Drug Device Combination Products Market Size, Share & Trends Analysis Report By Product (Transdermal Patches, Infusion Pumps, Inhalers, Drug Eluting Stents), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

药物器械组合产品市场的增长和趋势

根据Grand View Research, Inc.最新报告，到2030年，全球药械组合产品市场规模将达到2518亿美元，预计还将继续增长年復合增长率为 8.9%。

由于与微创技术相关的患者治疗效果得到改善，需求不断增长，这是该市场的一个高影响力驱动因素。 这些设备有助于早期诊断并缩短大多数外科手术的治疗时间。 需求不断增长的另一个原因是这些设备带来的痛苦最小、成本效率更高、安全性更高、功效更高、恢復更快和住院时间更短。

医疗保健监管机构越来越多地执行明确的上市前批准协议，预计将有助于製造商获得其产品的批准。 最近，美国FDA采用了精益管理流程映射方法，创建了一个更具凝聚力、精简、系统和协作的系统来审查上述产品。 据推测，这些当局发布的安全指南和建议将在未来增加这些产品的采用，并促进预测期内的整体增长。

由于药物在体内非预期部位吸收，与治疗药物相关的严重副作用和药物相互作用引发了对靶向治疗的需求，从而推动了对药物器械组合的需求。预计 例如，连续施用左旋多巴会导致长期并发症，例如运动波动、运动障碍、严重的代谢改变和神经毒性。 这些因素使得临床上必须纳入基于靶向治疗的替代方案，例如药物-器械组合产品。

药物器械组合产品市场报告亮点

  • 由于对于需要长期治疗的疾病的自我给药需求不断增加，透皮贴剂将在 2022 年占据产品市场份额
  • 由于慢性病患病率上升，预计吸入器领域在预测期内将呈现 10.3% 的复合年增长率
  • 由于该地区领先企业开展了广泛的新产品开发活动，北美地区在 2022 年占据了最大的地区份额，超过 40.5%。
  • 由于医疗保健支出不断增加以及医生对这些产品益处的认识不断提高，亚太地区预计未来几年将以有利的速度增长。
  • 主要市场参与者正在製定各种策略，例如新产品发布和销售合作伙伴关係，以获得市场渗透。
  • 由于高昂的运营成本、严格的监管框架和资本要求，进入壁垒保持在较高水平。

内容

第一章调查方法及范围

  • 调查方法
  • 调查范围和假设
  • 数据源列表

第 2 章执行摘要

第三章市场概况

第四章市场变量、趋势和范围

  • 市场细分和范围
  • 市场驱动因素分析
    • 对微创给药设备的需求不断增加
    • 技术进步
    • 现场护理治疗日益普及
    • 政府医疗保健机构持续采取干预措施
    • 意识水平提高
    • 完善医疗收费制度
  • 市场製约因素分析
    • 相关成本高
    • 药物输送的技术问题
  • 采用和增长前景图
  • 製药器械组合 - SWOT 分析，按因素（政治和法律、经济和技术）
  • 行业分析-波特

第五章药物器械组合产品市场：产品估算和趋势分析

  • 药物组合产品市场：产品变异分析
  • 输液泵
    • 2018-2030 年输液泵市场估计和预测（十亿美元）
    • 体积测量
    • 一次性
    • 注射器
    • 门诊
    • 可嵌入
    • 胰岛素
  • 骨科手术组合产品
    • 2018-2030 年骨科组合产品市场估计和预测（十亿美元）
    • 骨移植植入物
    • 抗生素骨水泥
  • 光动力治疗仪
    • 2018-2030 年光动力治疗设备市场估计和预测（十亿美元）
  • 透皮贴剂
    • 2018-2030 年透皮贴剂市场估计和预测（十亿美元）
  • 药物洗脱支架
    • 2018-2030 年药物洗脱支架市场估算和预测（十亿美元）
    • 冠状动脉支架
  • 伤口护理产品
    • 2018-2030 年伤口护理产品市场估计和预测（十亿美元）
  • 吸入器
    • 2018-2030 年吸入器市场估计和预测（十亿美元）
    • 干粉
    • 雾化器
    • 固定剂量
  • 抗菌导管
    • 2018-2030 年抗菌导管市场估计和预测（十亿美元）
    • 泌尿科
    • 心血管
    • 其他
  • 其他
    • 2018-2030 年其他市场估算和预测（十亿美元）

第 6 章药物器械组合产品市场：按产品划分的区域估计和趋势分析

  • 2022 年按地区划分的药物器械组合市场份额
  • 北美
    • 按产品划分，2018-2030 年
  • 欧洲
    • 按产品划分，2018-2030 年
  • 亚太地区
    • 按产品划分，2018-2030 年
  • 拉丁美洲
    • 按产品划分，2018-2030 年
  • MEA
    • 按产品划分，2018-2030 年

第七章竞争格局

  • 战略框架
  • 市场参与分类
  • 公司简介
    • Abbott Laboratories
    • Terumo Corporation
    • Stryker Corporation
    • Mylan NV
    • Medtronic
    • St.Jude Medical, Inc.
    • Allergan, Plc
    • Boston Scientific Corporation
    • Novartis AG
    • Teleflex Incorporated
    • CR Bard, Inc.
    • WLCore &Associates, Inc.
Product Code: GVR-1-68038-260-0

Drug Device Combination Products Market Growth & Trends

The global drug device combination product market size is expected to reach USD 251.8 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 8.9% during the forecast period. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduce treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.

Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.

Drug Device Combination Products Market Report Highlights

  • Transdermal patch held the dominant share by product in 2022 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
  • The inhalers segment is anticipated to exhibit a lucrative CAGR of 10.3% over the forecast period owing to rising prevalence of chronic diseases
  • North America held the largest share of over 40.5% in 2022 in terms of region owing to extensive new product development activities conducted by prominent players across this region
  • Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
  • Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration
  • High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Market Snapshot

Chapter 4. Market Variables, Trends & Scope

  • 4.1. Market segmentation & scope
  • 4.2. Market Driver Analysis
    • 4.2.1. Increasing demand for minimally invasive drug delivery devices
    • 4.2.2. Technological advancements
    • 4.2.3. Growing popularity of point of care treatment
    • 4.2.4. Consistent interventions by government healthcare organizations
    • 4.2.5. Increasing awareness levels
    • 4.2.6. Improving medical reimbursement framework
  • 4.3. Market Restraint Analysis
    • 4.3.1. High associated costs
    • 4.3.2. Technical challenges in drug delivery
  • 4.4. Penetration & Growth Prospect Mapping
  • 4.5. Drug Device Combination - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 4.6. Industry Analysis - Porter's

Chapter 5. Drug Device Combination Products Market: Product Estimates & Trend Analysis

  • 5.1. Drug device combination market: Product Movement Analysis
  • 5.2. Infusion Pumps
    • 5.2.1. Infusion pumps market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.2. Volumetric
      • 5.2.2.1. Volumetric market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.3. Disposable
      • 5.2.3.1. Disposable market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.4. Syringe
      • 5.2.4.1. Syringe market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.5. Ambulatory
      • 5.2.5.1. Ambulatory market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.6. Implantable
      • 5.2.6.1. Implantable market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.7. Insulin
      • 5.2.7.1. Insulin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.3. Orthopedic Combination Products
    • 5.3.1. Orthopedic combination products market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.3.2. Bone graft implants
      • 5.3.2.1. Bone graft implants market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.3.3. Antibiotic bone cement
      • 5.3.3.1. Antibiotic bone cement market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Photodynamic Therapy Devices
    • 5.4.1. Photodynamic therapy devices market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Transdermal Patches
    • 5.5.1. Transdermal patches market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Drug Eluting Stents
    • 5.6.1. Drug eluting stents market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.6.2. Coronary stents
      • 5.6.2.1. Coronary stents market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.2. Peripheral vascular stents market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Wound Care Products
    • 5.7.1. Wound care products market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.8. Inhalers
    • 5.8.1. Inhalers market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.2. Dry powder
      • 5.8.2.1. Dry powder market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.3. Nebulizers
      • 5.8.3.1. Nebulizers market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.4. Metered dose
      • 5.8.4.1. Metered dose market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Antimicrobial Catheters
    • 5.9.1. Antimicrobial catheters market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.2. Urological
      • 5.9.2.1. Urological market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.3. Cardiovascular
      • 5.9.3.1. Cardiovascular market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.4. Others
      • 5.9.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.10. Others
    • 5.10.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Drug Device Combination Products Market: Regional Estimates & Trend Analysis, By Product

  • 6.1. Drug Device Combination Market Share By Region, 2022
  • 6.2. North America
    • 6.2.1. North America market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.2.1.1. U.S. market estimates and forecasts
      • 6.2.1.2. Canada market estimates and forecasts
  • 6.3. Europe
    • 6.3.1. Europe market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.3.1.1. UK market estimates and forecasts
      • 6.3.1.2. Germany market estimates and forecasts
      • 6.3.1.3. France market estimates and forecasts
      • 6.3.1.4. Italy market estimates and forecasts
      • 6.3.1.5. Spain market estimates and forecasts
      • 6.3.1.6. Denmark market estimates and forecasts
      • 6.3.1.7. Sweden market estimates and forecasts
      • 6.3.1.8. Norway market estimates and forecasts
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.4.1.1. Japan market estimates and forecasts
      • 6.4.1.2. China market estimates and forecasts
      • 6.4.1.3. India market estimates and forecasts
      • 6.4.1.4. Australia market estimates and forecasts
      • 6.4.1.5. Thailand market estimates and forecasts
      • 6.4.1.6. South Korea market estimates and forecasts
  • 6.5. Latin America
    • 6.5.1. Latin America market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.5.1.1. Brazil market estimates and forecasts
      • 6.5.1.2. Mexico market estimates and forecasts
      • 6.5.1.3. Argentina market estimates and forecasts
  • 6.6. MEA
    • 6.6.1. MEA market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.6.1.1. South Africa market estimates and forecasts
      • 6.6.1.2. Saudi Arabia market estimates and forecasts
      • 6.6.1.3. UAE market estimates and forecasts
      • 6.6.1.4. Kuwait market estimates and forecasts

Chapter 7. Competitive Landscape

  • 7.1. Strategy framework
  • 7.2. Market participation categorization
  • 7.3. Company Profiles
    • 7.3.1. Abbott Laboratories
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Terumo Corporation
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Stryker Corporation
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Mylan N.V.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Medtronic
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. St.Jude Medical, Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Allergan, Plc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Boston Scientific Corporation
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Novartis AG
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Teleflex Incorporated
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. C.R. Bard, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. W.L.Core & Associates, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 3 U.S. drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 4 Canada drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 5 Europe drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 6 Germany drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 7 UK drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 8 France drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 9 Italy drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 10 Spain drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 11 Denmark drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 12 Sweden drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 13 Norway drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 14 Asia Pacific drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 15 Japan drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 16 China drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 17 India drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 18 Australia drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 19 Thailand drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 20 South Korea drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 21 Latin America drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 22 Brazil drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 23 Mexico drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 24 Argentina drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 25 MEA drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 26 South Africa drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 27 Saudi Arabia drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 28 UAE drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 29 Kuwait drug device combination market, by product, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market summary (USD Billion)
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Penetration & growth prospect mapping
  • FIG. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 8 Porter's five forces analysis
  • FIG. 9 Drug device combination market product outlook key takeaways
  • FIG. 10 Drug device combination market: Product movement analysis
  • FIG. 11 Global infusion pumps market, 2018 - 2030 (USD Billion)
  • FIG. 12 Global volumetric market, 2018 - 2030 (USD Billion)
  • FIG. 13 Global disposable market, 2018 - 2030 (USD Billion)
  • FIG. 14 Global syringe market, 2018 - 2030 (USD Billion)
  • FIG. 15 Global ambulatory market, 2018 - 2030 (USD Billion)
  • FIG. 16 Global implantable market, 2018 - 2030 (USD Billion)
  • FIG. 17 Global insulin market, 2018 - 2030 (USD Billion)
  • FIG. 18 Global orthopedic combination products market, 2018 - 2030 (USD Billion)
  • FIG. 19 Global bone graft implants market, 2018 - 2030 (USD Billion)
  • FIG. 20 Global antibiotic bone cement market, 2018 - 2030 (USD Billion)
  • FIG. 21 Global photodynamic therapy devices market, 2018 - 2030 (USD Billion)
  • FIG. 22 Global transdermal patches market, 2018 - 2030 (USD Billion)
  • FIG. 23 Global drug eluting stents market, 2018 - 2030 (USD Billion)
  • FIG. 24 Global coronary stents market, 2018 - 2030 (USD Billion)
  • FIG. 25 Global peripheral vascular stents market, 2018 - 2030 (USD Billion)
  • FIG. 26 Global wound care products market, 2018 - 2030 (USD Billion)
  • FIG. 27 Global inhalers market, 2018 - 2030 (USD Billion)
  • FIG. 28 Global dry powder market, 2018 - 2030 (USD Billion)
  • FIG. 29 Global nebulizers market, 2018 - 2030 (USD Billion)
  • FIG. 30 Global metered dose market, 2018 - 2030 (USD Billion)
  • FIG. 31 Global antimicrobial catheters market, 2018 - 2030 (USD Billion)
  • FIG. 32 Global urological market, 2018 - 2030 (USD Billion)
  • FIG. 33 Global cardiovascular market, 2018 - 2030 (USD Billion)
  • FIG. 34 Global others market, 2018 - 2030 (USD Billion)
  • FIG. 35 Global others market, 2018 - 2030 (USD Billion)
  • FIG. 36 Regional market place: Key takeaways
  • FIG. 37 Regional outlook, 2015 & 2024
  • FIG. 38 North America drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 39 U.S. drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 40 Canada drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 41 Europe drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 42 Germany drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 43 UK drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 44 France drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 45 Italy drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 46 Spain drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 47 Denmark drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 48 Sweden drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 49 Norway drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 50 Asia Pacific drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 51 Japan drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 52 China drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 53 India drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 54 Australia drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 55 Thailand drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 56 South Korea drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 57 Latin America drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 58 Brazil drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 59 Mexico drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 60 Argentina drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 61 MEA drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 62 South Africa drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 63 Saudi Arabia drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 64 UAE drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 65 Kuwait drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 66 Strategy framework
  • FIG. 67 Participant categorization